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Abstract
Objectives Discrete choice experiments (DCEs) are increasingly advocated as a way to quantify preferences for health. How-
ever, increasing support does not necessarily result in increasing quality. Although specific reviews have been conducted in 
certain contexts, there exists no recent description of the general state of the science of health-related DCEs. The aim of this 
paper was to update prior reviews (1990–2012), to identify all health-related DCEs and to provide a description of trends, 
current practice and future challenges.
Methods A systematic literature review was conducted to identify health-related empirical DCEs published between 2013 
and 2017. The search strategy and data extraction replicated prior reviews to allow the reporting of trends, although addi-
tional extraction fields were incorporated.
Results Of the 7877 abstracts generated, 301 studies met the inclusion criteria and underwent data extraction. In general, 
the total number of DCEs per year continued to increase, with broader areas of application and increased geographic scope. 
Studies reported using more sophisticated designs (e.g. D-efficient) with associated software (e.g. Ngene). The trend towards 
using more sophisticated econometric models also continued. However, many studies presented sophisticated methods with 
insufficient detail. Qualitative research methods continued to be a popular approach for identifying attributes and levels.
Conclusions The use of empirical DCEs in health economics continues to grow. However, inadequate reporting of meth-
odological details inhibits quality assessment. This may reduce decision-makers’ confidence in results and their ability to 
act on the findings. How and when to integrate health-related DCE outcomes into decision-making remains an important 
area for future research.
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Key Points 
Quantifying preferences for healthcare is becoming 
increasingly popular; however, there exists no recent 
description of how health-related discrete choice experi-
ments (DCEs) are being employed.
This study identified changes in experimental design, 
analytical methods, validity tests, qualitative methods 
and outcome measures over the last 5 years.
To facilitate quality assessment and better integration 
into health decision-making, future DCE reports should 
include more complete information, which might be 
achieved by developing reporting guidelines specifically 
for DCEs.
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and outcome measures will be described by comparing the 
results to those of prior reviews. For the sake of general-
ity and to allow examination of trends based on consistent 
data extraction methods, this comparison will focus on the 
broad reviews cited above, rather than on narrower reviews 
of DCEs covering specific study designs or disease areas 
[21–41]. Recent developments in DCE methods will be 
incorporated by including new data elements not reported 
in previous reviews. Potential challenges and recommenda-
tions for future research will also be identified.
2  Methods
The current systematic review continued the work conducted 
in the prior broad DCE reviews [6, 7, 11] by focusing on 
DCE1 applications published between 2013 and 2017. The 
methodology for this systematic review built on that of the 
prior reviews to allow comparison of results across review 
periods and identification of trends. The search was initiated 
in May 2015 and updated in February 2016 and January 
2018. We used the same search engine (PubMed) that was 
used in the latest review by Clark et al. [6] and generally used 
the same search terms. We decided to exclude the search 
terms ‘conjoint’ and ‘dce’, since these yielded too many 
irrelevant results (particularly due to the rise of dynamic 
contrast-enhanced imaging in gene expression profiling) and 
would have substantially increased the number of abstracts 
to be reviewed. The final search terms included ‘discrete 
choice experiment’, ‘discrete choice experiments’, ‘discrete 
choice modeling’, ‘discrete choice modelling’, ‘discrete 
choice conjoint experiment’, ‘stated preference’, ‘part-worth 
utilities’, ‘functional measurement’, ‘paired comparisons’, 
‘pairwise choices’, ‘conjoint analysis’, ‘conjoint measure-
ment’, ‘conjoint studies’, ‘conjoint choice experiment’ and 
‘conjoint choice experiments’. A study was included if it was 
applied to health, included a discrete choice exercise (rather 
than rating or ranking), focused on human beings and was 
published as a full-text article in English between January 
2013 and December 2017. Consistent with prior reviews, 
DCEs without empirical data (e.g. methodological studies) 
and studies of samples already included in our review were 
excluded.
To ensure consistency of data extraction and assist with 
synthesis of results, the authors used an extraction tool, 
1 In this review, best–worst scaling (BWS) case 1 and 2 are distin-
guished from case 3. Since case 1 and 2 BWS do not involve attrib-
ute-based comparisons between two or more alternatives, they were 
excluded from this review [42], consistent with the previous review 
[6]. Case 3 BWS, however, involves an attribute-based comparison 
between two or more alternatives and is considered an extension of 
DCEs in the literature [367, 42]. Therefore, case 3 BWS applications 
were included in this review.
1 Introduction
In recent years, there have been increased calls for patient 
and public involvement in healthcare decision-making [1, 2]. 
Patient or public involvement can support decision-making 
at multiple levels: individual (shared decision-making), pol-
icy (patient experts on panels) and commissioning (incorpo-
rating patient preferences in technology evaluations or health 
state valuation). Views can be elicited qualitatively, quan-
titively or using mixed-methods approaches [3]. Example 
methods include interviews, focus groups and stated prefer-
ence techniques such as the standard gamble or time trade-
off. Studies by the Medical Device Innovation Consortium 
(MDIC) [4] and Mahieu et al. [5] highlighted a wide variety 
of methods to measure both stated and revealed preferences 
in healthcare.
Among the quantitative methods for eliciting stated 
health preferences, discrete choice experiments (DCEs) are 
increasingly advocated [6]. In a DCE individuals are asked 
to select their preferred (and/or least preferred) alternative 
from a set of alternatives. DCEs are grounded in theories 
which assume that (1) alternatives can be described by their 
attributes, (2) an individual’s valuation depends upon the 
levels of these attributes, and (3) choices are based on a 
latent utility function [7–10]. The theoretical foundations 
have implications for the experimental design (principles to 
construct alternatives and choice sets) and the probabilistic 
models used to analyse the choice data [7].
Previously conducted broad reviews by Ryan and Gerard 
(1990–2000) [11], de Bekker-Grob et al. (2001–2008) [7] 
and Clark et al. (2009–2012) [6] identified a number of 
methodological challenges of DCEs (e.g. how to choose 
among orthogonal, D-efficient and other designs or how to 
account for preference heterogeneity when analysing choice 
data). These reviews, as well as published checklists [12] 
and best-practice guidelines [13–17], have been developed 
to provide specific guidance and potentially improve qual-
ity [12, 18]. However, it is unknown whether the challenges 
identified in prior reviews are still relevant or whether 
there has been a response to the published suggestions and 
guidelines. Furthermore, although health-related DCEs are 
increasingly advocated by organisations such as the MDIC 
[4], their use for actual decision-making in health remains 
limited [7, 13]. Key barriers to their wider use in policy 
include concerns about the robustness and validity of the 
method and the quality of applied studies [19, 20].
This paper seeks to provide a current overview of the 
applications and methods used by DCEs in health eco-
nomics. This overview will be created by systematically 
reviewing DCE literature and extracting data from the 
period 2013–2017. In addition, historical trends in experi-
mental design, analytical methods, validation procedures 
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available in Appendix A of the Electronic Supplementary 
Material, initially developed using the criteria of Clark et al. 
[6]. We first considered areas of application (e.g. patient 
consumer experience, valuing health outcomes) and back-
ground information (country of origin, number and type 
of attributes, number of choice sets, survey administration 
method), followed by more detailed information about the 
experimental design (type, plan, use of blocking, design 
software, design source, method used to create choice sets, 
number of alternatives, presence of an opt-out or status quo 
option, sample size and type), data analysis (model, analy-
sis software, model details), validity checks (external and 
internal), use of qualitative methods (type and rationale) 
and presented outcome measures. The authors tested the 
extraction tool and discussed initial results. To fully capture 
current DCE design methods, the following data elements 
were added to the original data extraction tool: number of 
alternatives, presence of an opt-out or status quo, sample 
size, use of blocking, use of a Bayesian design approach, 
software for econometric analyses and the type of qualitative 
research methods reported. With regard to analysis methods, 
this review also extracted additional information on the use 
of scale-adjusted latent class, heteroskedastic conditional 
logit and generalised multinomial models. Studies were also 
categorised by journal type.
Each author extracted data from a group of articles, 
checking online appendices and supplementary materials 
where relevant. A subsample of studies (20%) was dou-
ble-checked by V.S. for quality control. We categorised 
the extracted data and reported the results as percentages. 
Results for the econometric analysis models were catego-
rised based on the three key characteristics of the multino-
mial logit model (Fig. 1): (1) the assumption that error terms 
are independent and identically distributed (IID) according 
to the extreme value type I distribution, (2) independence of 
irrelevant alternatives (IIA) (resulting from the first charac-
teristic) and (3) the presence or absence of preference het-
erogeneity [7]. The IID characteristic limits flexibility in 
estimating the error variance, whereas IIA is about the flex-
ibility of the substitution pattern (how flexible respondents 
are to substitute between choices), and assumptions about 
preference heterogeneity determine whether preferences are 
allowed to vary across respondents.
3  Results
3.1  Search Results
A total of 7877 abstracts were identified from the beginning 
of 2013 until the end of 2017. After abstract and full-text 
review, 301 DCEs (including six case 3 best–worst scaling 
[BWS] studies) met the inclusion criteria and were selected 
Fig. 1  Econometric analysis model overview
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for data extraction (see Fig. 2) [43–343]. Figure 3 depicts the 
total number of DCE applications in health across the differ-
ent review periods: 1990–2000, 2001–2008, 2009–2012 and 
2013–2017. The 2009–2012 review reported that the number 
of studies had increased to 45 per year on average [6]. The 
current review period found 60 studies per year on average, 
with a high of 98 studies in 2015 and a low of 32 studies 
in 2017 (Fig. 3). Figure 3 also shows that the increase in 
DCE applications between the prior review periods and the 
current review period was less consistent than the increases 
observed in prior periods.
3.2  Areas of Application
Prior reviews mentioned that although DCEs were originally 
introduced in health economics to value patient or consumer 
experience, the use of DCEs has broadened considerably [6, 
344]. Table 1 summarises information about the different 
areas of application of DCEs for each review period (Appen-
dix B of the Electronic Supplementary Material contains 
figures based on the tables in this review). Compared to 
the latest review period, the largest overall shifts occurred 
in the areas of patient consumer experience (category A), 
trade-offs between health outcomes and patient or consumer 
Fig. 2  Flow diagram of systematic literature review to identify discrete choice experiments (DCEs)
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experience factors (category C), and health professionals’ 
preferences for treatment or screening (category G). In the 
current review period, 8% of studies valued health out-
comes such as ‘heart attacks avoided’ (category B, 23 stud-
ies, e.g. studies [148, 152, 153, 162, 170]), 4% estimated 
utility weights within the quality-adjusted life year (QALY) 
framework (category D, 13 studies, e.g. [218, 226–228, 
230]), 6% focused on job choices (category E, 17 studies, 
e.g. [231, 236, 238, 242, 247]), and 9% developed priority-
setting frameworks (category F, 27 studies, e.g. [248, 253, 
270, 272, 274]).
Among the DCEs reviewed, the most common journal 
focus was health services research (n = 139; 46%). About a 
third (n = 102; 34%) of articles were published in specialty-
focused medical journals such as Vaccine (five studies [66, 
131, 146, 311, 313]) or the British Journal of Cancer (three 
studies [47, 70, 171]). Fifty-one (17%) were published in 
general medical journals such as PLoS One (20 studies, e.g. 
[44, 64, 81, 91, 99]) and BMJ Open (five studies [100, 102, 
109, 169, 264]). More details can be found in Appendix C 
of the Electronic Supplementary Material.
3.3  Background Information About DCEs
The reviews from Ryan and Gerard [11], de Bekker-Grob 
et al. [7] and Clark et al. [6] provided detailed information 
about study characteristics. Information for the current 
review period is described in the sections below. Table 2 
parts (a) and (b) report the current information alongside 
data from the prior reviews.
3.3.1  Country of Origin
Table 2a shows that UK-based studies made up a relatively 
high proportion of published DCEs (17%, 50 studies), as did 
studies from the US (17%, 50 studies), Australia (10%, 30 
studies), the Netherlands (15%, 44 studies), Germany (9%, 
28 studies) and Canada (8%, 25 studies). DCEs were also 
popular in other European countries, for example, Italy (3%, 
eight studies) and Sweden (2%, six studies) (not shown). We 
also observed an increase in studies coming from ‘other’ 
countries, from 0% to 34% across the four review periods, 
which reflects an upwards trend towards applying DCEs in 
middle- and low-income countries (e.g. Cameroon [239], 
Ghana [244], Laos [232], Malawi [254] and Vietnam [122]).
3.3.2  Attributes, Choices and Survey
In the current review period, the number of attributes per 
alternative in DCEs ranged from two to 21, with a median of 
five. We observed a slight decrease in number of attributes; 
the modal category was 4–5 (39%, 117 studies). In line with 
prior reviews, most studies (82%, 247 studies) included four 
to nine attributes. For the period 2013–2017, most studies 
included a monetary (50%, 150 studies), time-related (39%, 
117 studies), or risk-related (44%, 133 studies) attribute. The 
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Fig. 3  Number of discrete choice experiment (DCE) applications by publication year
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proportion of studies including time-related and health status 
(24%, 71 studies) attributes decreased.
Most DCEs in the current period included nine to 16 
choices per individual (54%, 162 studies), with a median 
of 12 (minimum 1, maximum 32). Prior reviews mentioned 
increases in online administration of DCEs. This trend con-
tinued in the current review period, with 57% of the DCEs 
conducted online (172 studies), whereas the number of 
DCEs which used pencil and paper dropped to 23% (69 stud-
ies). These self-completed DCEs remained the main source 
of survey administration.
3.3.3  Alternatives and Sample
Prior reviews did not collect data about the number of alter-
natives included in each DCE or whether an opt-out or sta-
tus quo option was included. For the current period, most 
of the studies (83%, 251 studies) included two alternatives 
(not including any opt-out or status quo option), with 8% 
(23 studies) not clearly reporting the number of included 
alternatives (Table 2b). The majority of the studies (64%, 
194 studies) did not include an opt-out or status quo option.
The prior reviews covering the period 1990–2012 did not 
extract data about the sample size. In the current period, the 
mean and median sample size were 728 and 401, respec-
tively. Sample size ranged from a minimum of 35 [116] to a 
maximum of 30,600 respondents [148]. Most of the samples 
included patients (37%, 110 studies) or the general public 
(27%, 81 studies). A large number of DCEs sampled ‘other’ 
populations (31%, 93 studies) such as healthcare workers, 
healthcare students or a mixture of these.
3.4  Experimental Design
Experimental design (planning of the alternatives and choice 
sets) is crucial to the conduct of a DCE. The review from de 
Bekker-Grob et al. [7] describes DCE design in detail. For 
more information about the choices researchers have to make 
when designing the experimental part of a DCE, we also 
refer to a key checklist and best practice example [14, 15].
3.4.1  Design Type, Design Plan and Blocking
As in prior review periods, most DCEs made use of a frac-
tional design (89%, 269 studies) (Table 3). Additionally, 
we observed that for the current review period, the design 
plan of DCEs most frequently focused on main effects only 
(29%, 86 studies). This is a decrease compared to the peri-
ods 1990–2000, 2001–2008 and 2009–2012, with 74%, 
89% and 55%, respectively. The percentage of DCEs not 
clearly reporting design plan information increased to 49% 
(147 studies) for 2013–2017. When generating the experi-
mental design, blocking, creating different versions of the Ta
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Table 2  DCE Background information
DCE discrete choice experiment, N/A not applicable, N/C not collected (data were not collected for this specific category)
a Numbers of individual studies might not add up to total Ns as some studies addressed multiple topics
b Percentages might not add up to 100% because some studies addressed multiple topics and because of rounding error
Item Category 1990–2000 2001–2008 2009–2012 Current: 2013–2017
N = 34a (%)b N = 114a (%)b N = 179a (%)b N = 301a (%)b
(a)
Country of origin Australia 6 (18) 13 (11) 14 (8) 30 (10)
Canada 1 (3) 6 (5) 23 (13) 25 (8)
Germany 0 (0) 3 (3) 18 (10) 28 (9)
Netherlands 0 (0) 5 (4) 27 (15) 44 (15)
UK 20 (59) 55 (48) 39 (22) 50 (17)
US 7 (21) 14 (12) 28 (16) 50 (17)
Other 0 (0) 13 (11) 45 (25) 102 (34)
Number of attributes 2–3 5 (15) 15 (13) 14 (8) 30 (10)
4–5 10 (29) 50 (44) 57 (32) 117 (39)
6 9 (26) 30 (26) 61 (34) 67 (22)
7–9 4 (12) 15 (13) 41 (23) 63 (21)
10 2 (6) 2 (2) 5 (3) 4 (1)
> 10 4 (12) 2 (2) 5 (3) 12 (4)
Not clearly reported N/C N/C N/C N/C N/C N/C 8 (3)
Attributes covered Monetary measure 19 (56) 61 (54) 102 (57) 150 (50)
Time 25 (74) 58 (51) 118 (66) 117 (39)
Risk 12 (35) 35 (31) 106 (59) 133 (44)
Health status 19 (56) 62 (54) 109 (61) 71 (24)
Health care 28 (82) 79 (69) 129 (72) 104 (35)
Other 3 (9) 17 (15) 88 (49) 144 (48)
Number of choices per individual 8 or less 13 (38) 45 (39) 36 (20) 86 (29)
9–16 choices 18 (53) 43 (38) 113 (63) 162 (54)
> 16 choices 2 (6) 21 (18) 30 (17) 44 (15)
Not clearly reported 1 (3) 5 (4) 5 (3) 9 (3)
Administration of survey Self-completed questionnaire (paper) 27 (79) 76 (67) 86 (48) 69 (23)
Self-completed questionnaire (online) 3 (9) 13 (11) 75 (42) 172 (57)
Interviewer administered 3 (9) 22 (19) 34 (19) 44 (15)
Other N/C N/C N/C N/C N/C N/C 5 (2)
Not clearly reported 1 (3) 9 (8) 7 (4) 11 (4)
(b)
Number of alternatives (not including opt-
out/status quo)
2 N/C N/C N/C N/C N/C N/C 251 (83)
3 N/C N/C N/C N/C N/C N/C 20 (7)
4 N/C N/C N/C N/C N/C N/C 5 (2)
5 N/C N/C N/C N/C N/C N/C 2 (1)
Not clearly reported N/C N/C N/C N/C N/C N/C 23 (8)
Number of studies with opt-out/status quo Yes N/C N/C N/C N/C N/C N/C 98 (33)
No N/C N/C N/C N/C N/C N/C 194 (64)
Not clearly reported N/C N/C N/C N/C N/C N/C 9 (3)
Sample size Mean N/C N/C N/C N/C N/C N/C 728 N/A
Median N/C N/C N/C N/C N/C N/C 401 N/A
Type of sample Patients 15 (44) N/C N/C N/C N/C 110 (37)
Healthcare workers N/C N/C N/C N/C N/C N/C 39 (13)
General public 11 (32) N/C N/C N/C N/C 81 (27)
Other 8 (24) N/C N/C N/C N/C 93 (31)
Not clearly reported N/C N/C N/C N/C N/C N/C 5 (2)
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experiment for different respondent groups, can be used to 
reduce the cognitive burden of respondents by reducing the 
total number of choices per respondent [345]. Reviews for 
the period 1990–2012 did not collect information about 
blocking. Data for the current period showed that 50% 
(150 studies) reported using blocking when generating the 
experimental design. On average, studies with blocking had 
709 participants, each of whom completed 11 choice sets, 
whereas studies with unblocked designs had 439 partici-
pants, each of whom completed 13 choice sets.
3.4.2  Design Software
Ngene became the most popular software tool in the cur-
rent period for generating experimental designs (21%, 62 
studies, e.g. [53, 63, 139, 268, 319]). SAS (18%, 54 studies, 
e.g. [262, 290, 296, 300, 316]) and Sawtooth (16%, 47 stud-
ies, e.g. [46, 141, 207, 276, 323]) remained popular tools. 
Compared to prior review periods, we observed an increase 
in the percentage of studies not clearly indicating what soft-
ware was used to generate the experimental design (33%, 99 
studies, e.g. [44, 144, 177, 204, 299]).
Table 3  Experimental design information DCEs
DCE discrete choice experiment, N/C not collected (data were not collected for this specific category)
a Numbers of individual studies might not add up to total Ns as some studies addressed multiple topics
b Percentages might not add up to 100% because some studies addressed multiple topics and because of rounding error
Item Category 1990–2000 2001–2008 2009–2012 Current: 
2013–2017
N = 34a (%)b N = 114a (%)b N = 179a (%)b N = 301a (%)b
Design type Full factorial 4 (12) 0 (0) 9 (5) 13 (4)
Fractional 25 (74) 114 (100) 158 (88) 269 (89)
Not clearly reported 5 (15) 0 (0) 12 (7) 19 (6)
Design plan Main effects only 25 (74) 100 (89) 98 (55) 86 (29)
Main effects and two-way interactions 2 (6) 6 (5) 23 (13) 52 (17)
Not applicable 4 (12) 0 (0) 5 (3) 5 (2)
Other N/C N/C N/C N/C N/C N/C 11 (4)
Not clearly reported 3 (9) 8 (7) 52 (29) 147 (49)
Blocking Yes N/C N/C N/C N/C N/C N/C 150 (50)
No N/C N/C N/C N/C N/C N/C 60 (20)
Not clearly reported N/C N/C N/C N/C N/C N/C 91 (30)
Design software Ngene N/C N/C N/C N/C N/C N/C 62 (21)
SAS 0 (0) 14 (12) 41 (23) 54 (18)
Sawtooth 2 (6) 5 (4) 30 (17) 47 (16)
SPEED 13 (38) 22 (19) 9 (5) 1 (0)
SPSS 2 (6) 14 (12) 13 (7) 20 (7)
Not applicable N/C N/C N/C N/C N/C N/C 11 (3)
Other 2 (6) N/C N/C 27 (15) 7 (2)
Not clearly reported N/C N/C 4 (4) 9 (5) 99 (33)
Design source Website 0 (0) 3 (3) 9 (5) 4 (1)
Expert 4 (12) 4 (4) 11 (6) 5 (2)
Not clearly reported 9 (26) 42 (37) 30 (17) 215 (71)
Methods to cre-
ate choice sets
Orthogonal: single profiles (binary choices) 3 (9) 12 (11) 2 (1) 7 (2)
Orthogonal: random pairing 18 (53) 19 (17) 18 (10) 12 (4)
Orthogonal: pairing with constant comparator 6 (18) 23 (20) 5 (3) 0 (0)
Orthogonal: foldover-random pairing 0 (0) 1 (1) 4 (2) 2 (1)
Orthogonal: foldover 0 (0) 11 (10) 34 (19) 26 (9)
D-efficiency 0 (0) 14 (12) 54 (30) 105 (35)
Bayesian D-efficiency N/C N/C N/C N/C N/C N/C 23 (8)
Other 4 (12) 2 (2) 27 (15) 26 (9)
Not clearly reported 3 (9) 32 (28) 39 (22) 100 (33)
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3.4.3  Methods to Create Choice Sets
The upwards trend in the use of D-efficient (35%, 105 stud-
ies) experimental designs continued in the current review 
period. Correspondingly, fewer DCEs used orthogonal 
arrays through methods such as single profiles, random pair-
ing or the foldover technique (Table 3). As with the experi-
mental design characteristics mentioned in the previous 
sections, we observed that an increasing number of studies 
(33%, 100 studies in 2013–2017) did not clearly report the 
methods used to create choice sets.
3.5  Econometric Analysis Methods
Information about the different econometric analysis meth-
ods and the appropriateness of these methods for different 
DCE applications is described in great detail in the prior 
reviews [6, 7, 11]. More information can be found in papers 
by Louviere and Lancsar [12], Bridges et al. [14] and Hauber 
et al. [17]. Table 4 parts (a) and (b) summarise informa-
tion about econometric analyses from the current and prior 
review periods.
Table 4  Econometric analysis details DCEs
DCE discrete choice experiment, N/A not applicable, N/C not collected (data were not collected for this specific category)
a Numbers of individual studies might not add up to total Ns as some studies addressed multiple topics
b Percentages might not add up to 100% because some studies addressed multiple topics and because of rounding error
Item Category 1990–2000 2001–2008 2009–2012 Current: 
2013–2017
N = 34a (%)b N = 114a (%)b N = 179a (%)b N = 301a (%)b
(a)
Econometric analysis model Random effects probit (random inter-
cept)
18 (53) 47 (41) 18 (10) 17 (6)
Logit 1 (3) 13 (11) 18 (10) 0 (0)
Multinomial logit 6 (18) 25 (22) 86 (45) 116 (39)
Random effects logit (random intercept) 1 (3) 6 (5) 14 (8) 15 (5)
Mixed logit (random parameter) 1 (3) 6 (5) 45 (25) 118 (39)
Latent class 0 (0) 1 (1) 7 (4) 36 (12)
Nested logit 0 (0) 5 (4) 4 (2) 6 (2)
Scale-adjusted latent class N/C N/C N/C N/C N/C N/C 2 (1)
Heteroskedastic multinomial logit N/C N/C N/C N/C N/C N/C 11 (4)
Generalised multinomial logit N/C N/C N/C N/C N/C N/C 12 (4)
Probit 6 (18) 8 (7) 4 (2) 7 (2)
Other 1 (3) 4 (4) 32 (18) 25 (8)
Not clearly reported 2 (6) 4 (4) 2 (1) 7 (2)
(b)
Software for econometric analysis Nlogit N/C N/C N/C N/C N/C N/C 65 (22)
Biogeme N/C N/C N/C N/C N/C N/C 5 (2)
Sawtooth N/C N/C N/C N/C N/C N/C 16 (5)
R N/C N/C N/C N/C N/C N/C 10 (3)
Stata N/C N/C N/C N/C N/C N/C 94 (31)
SAS N/C N/C N/C N/C N/C N/C 17 (6)
Other N/C N/C N/C N/C N/C N/C 15 (5)
Not clearly reported N/C N/C N/C N/C N/C N/C 79 (26)
Mixed logit/random parameter 
logit-additional information
Number of studies with additional 
information
N/C N/C N/C N/C 38 (21) 65 (22)
Mean number of draws N/C N/C N/C N/C N/C N/C 1354 N/A
Median number of draws N/C N/C N/C N/C N/C N/C 1000 N/A
Distributional assumption: normal 
distribution
N/C N/C N/C N/C 20 (52) 53 (18)
Distributional assumption: other distri-
bution/unclear
N/C N/C N/C N/C 19 (50) 12 (4)
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3.5.1  Econometric Analysis Model, Software 
and Preference Heterogeneity
We present information about econometric analysis mod-
els according to the taxonomy described in the “Methods” 
section and visualised in Fig. 1. Reviews for the periods 
1990–2000 and 2001–2008 reported that most DCEs used 
random-effects (random-intercept) probit models to analyse 
preference data (53% and 41%, respectively). The review 
for the period 2009–2012 showed a shift to the use of other 
methods like multinomial logit models (45%) and mixed 
(random-parameter) logit models (25%). For the current 
review period, this trend continued (see Table 4a). Most 
DCEs in 2013–2017 reported the use of mixed logit models 
(39%, 118 studies, e.g. [47, 271, 301, 314, 318]) or multino-
mial logit models (39%, 116 studies, e.g. [92, 110, 166, 294, 
339]) to analyse preference data. The current review period 
also showed an increase in the use of latent class models 
(12%, 36 studies, e.g. [38, 91, 139, 165, 269]) and other 
econometric analysis models. Examples include generalised 
multinomial logit (4%, 12 studies, e.g. [97, 124, 157, 174, 
240]) and heteroskedastic multinomial logit (4%, 11 studies, 
e.g. [134, 139, 184, 256, 309]).
Prior reviews did not collect data about the software used 
for econometric analysis. For the current review period, 
Table 4b shows that most DCEs made use of Stata (31%, 
94 studies, e.g. [91, 110, 138, 149, 213]) or Nlogit (22%, 
65 studies, e.g. [94, 171, 204, 282, 346]) to conduct econo-
metric analysis. However, 26% (79 studies, e.g. [101, 184, 
211, 231, 330]) did not clearly report information about the 
software used.
Among the studies that used mixed logit models 
to account for preference heterogeneity in the period 
2013–2017, 22% (65 studies) included additional informa-
tion about the distributional assumptions used to conduct 
the mixed logit analysis and the number of distributional 
draws (e.g. Halton draws) used to simulate preference het-
erogeneity. This percentage is similar to the percentage for 
the period 2009–2012, which was 21%. The mean number 
of draws for the current review period was 1354 (median 
1000, minimum 50, maximum 10,000), and 18% of the 
DCEs (53 studies) assumed that parameters followed the 
normal distribution.
3.6  Validity Checks and Qualitative Methods
DCEs are based on responses to hypothetical choices (stated 
preferences), so internal and external validity checks provide 
a crucial opportunity to assess data quality or to compare 
stated preferences from DCEs with revealed preferences. 
As Clark et al. [6] observed in their review, there is often 
little reported about the tests for external validity, possibly 
Table 5  Details of validity checks and qualitative methods
N/C not collected (data were not collected for this specific category)
a Numbers of individual studies might not add up to total Ns as some studies addressed multiple topics
b Percentages might not add up to 100% because some studies addressed multiple topics and because of rounding error
Item Category 1990–2000 2001–2008 2009–2012 Current: 
2013–2017
N = 34a (%)b N = 114a (%)b N = 179a (%)b N = 301a (%)b
External validity tested Yes 0 (0) 1 (1) 2 (1) 7 (2)
No 34 (100) 113 (99) 177 (99) 294 (98)
Internal validity tested Non-satiation (dominated questions) 15 (44) 56 (49) 36 (20) 50 (17)
Transitivity (a > b, b > c then c > a) 3 (9) 5 (4) 2 (1) 2 (1)
Sen’s expansion and contraction 0 (0) 2 (2) 2 (1) 2 (1)
Internal compensatory (1 attribute) 12 (35) 36 (32) 30 (17) 18 (6)
Other N/C N/C N/C N/C N/C N/C 102 (34)
Not clearly reported/not tested N/C N/C N/C N/C N/C N/C 189 (63)
Type of qualitative method used Interviews N/C N/C N/C N/C N/C N/C 151 (50)
Focus groups N/C N/C N/C N/C N/C N/C 54 (18)
Other N/C N/C N/C N/C N/C N/C 53 (18)
No qualitative method used N/C N/C N/C N/C N/C N/C 43 (14)
Rationale using qualitative methods Attribute selection 6 (18) 79 (69) 90 (50) 160 (53)
Level selection 6 (18) 38 (33) 73 (41) 134 (44)
Pre-testing questionnaire 16 (47) 36 (32) 73 (41) 113 (38)
Understanding results/responses 0 (0) 5 (4) 14 (8) 12 (4)
Not clearly reported/other N/C N/C N/C N/C N/C N/C 5 (2)
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because validating hypothetical choice scenarios is difficult 
[347]. Perhaps for this reason, the review covering the period 
1990–2000 did not extract specific information about external 
validity tests. In the reviews from 2001–2012, only a very 
small proportion (1%) of the DCEs reported any details about 
their investigations into external validity. The current review 
period showed that 2% (seven studies [55, 93, 147, 184, 185, 
195, 248]) reported using external validity tests (Table 5).
For detailed information about the different internal valid-
ity tests, we refer to the prior review papers [6, 7, 11]. In the 
current review period, the percentage of studies that included 
internal validity checks ranged from a maximum of 17% 
(50 studies) for non-satiation checks to 6% (18 studies) for 
internal compensatory checks. Internal compensatory checks 
were reported less frequently than in earlier review periods. 
For the current review period, ‘other’ validity checks such 
as tests for theoretical and face validity and consistency were 
used frequently (34%, 102 studies).
Another way to enhance quality in a DCE is to comple-
ment the quantitative study with qualitative methods [35]. 
For the current review period, 86% (258) of the DCEs used 
qualitative methods to enhance the process and/or results. 
Most DCEs used interviews (50%, 151 studies) or focus 
group techniques (18%, 54 studies). Qualitative methods 
were usually used to inform attribute (53%, 160 studies) 
and/or level (44%, 134 studies) selection, which follows the 
overall upwards trend reported in prior reviews. The propor-
tion of DCEs using qualitative methods for questionnaire 
pre-testing (38%, 113 studies) was similar to the level in 
the previous review period. Overall, just as in the previous 
review periods, few studies in the current review period (4%, 
12 studies) used qualitative methods to improve the under-
standing of results/responses.
3.7  Outcome Measures
Information about the trends regarding the presented out-
come measures is presented in Table 6.
As mentioned in prior reviews, DCEs often presented 
their outcomes in terms of willingness to pay (WTP), a mon-
etary welfare measure or a utility score [6, 7, 11]. Use of 
these methods has declined over the past two review periods 
(2001–2012), and use of utility scores decreased from 24% 
to 8% over the past three periods (1990–2012). Relative to 
the previous period, we observed increases in the use of util-
ity scores (17%, 50 studies, e.g. [61, 128, 141, 164, 317]), 
odds ratios (10%, 30 studies, e.g. [80, 146, 200, 234, 280]) 
and probability scores (13%, 38 studies, e.g. [122, 154, 198, 
272, 277]). We also collected information about willingness-
to-accept (WTA) measures (4%, 13 studies, e.g. [53, 94, 250, 
322, 338]) and regression coefficients (56%, 169 studies, e.g. 
[44, 57, 231, 244, 276]), which were not collected in previ-
ous reviews. The proportion of studies with ‘other’ outcome 
measures remained near one half (49%, 147 studies, e.g. [48, 
87, 114, 207, 273]). Examples from this category include 
(predicted) choice shares, maximum acceptable risk, relative 
importance and ranking.
4  Discussion
In this study, we reviewed DCEs published between 2013 
and 2017. We followed the methods of prior reviews and 
compared our extraction results to those reviews to iden-
tify trends. We identified that DCEs have continued to 
increase in number and have been undertaken in more and 
more countries. Studies reported using more sophisticated 
Table 6  Presented outcome measures of DCEs
DCE discrete choice experiment, N/C not collected (data were not collected for this specific category), WTA willingness to accept, WTP willing-
ness to pay
a Numbers of individual studies might not add up to total Ns as some studies addressed multiple topics
b Percentages might not add up to 100% because some studies addressed multiple topics and because of rounding error
Item Category 1990–2000 2001–2008 2009–2012 Current: 2013–
2017
N = 34a (%)b N = 114a (%)b N = 179a (%)b N = 301a (%)b
Presented out-
come measure
Per WTP unit 10 (29) 44 (39) 54 (30) 80 (27)
Per WTA unit N/C N/C N/C N/C N/C N/C 13 (4)
Per risk unit 3 (9) 2 (2) 4 (2) 9 (3)
Monetary welfare measure 5 (15) 14 (12) 4 (2) 8 (3)
Utility score 8 (24) 18 (16) 14 (8) 50 (17)
Odds ratio 1 (3) 9 (8) 14 (8) 30 (10)
Probability score 1 (3) 15 (13) 14 (8) 38 (13)
Coefficients N/C N/C N/C N/C N/C N/C 169 (56)
Other N/C N/C N/C N/C 90 (50) 147 (49)
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designs with associated software, for example, D-efficient 
designs generated using Ngene. The trend towards the use 
of more sophisticated econometric models has also contin-
ued. However, many studies presented sophisticated methods 
with insufficient detail. For example, we were not able to 
check whether the results had the correct interpretation or 
whether the authors had conducted the appropriate diag-
nostics (e.g. checked that the data possessed the IIA charac-
teristic). Qualitative methods have continued to be popular 
as an approach to select attributes and levels, which might 
improve validity. In this study, we also extracted data in sev-
eral new categories, for example, sample size and type, the 
use of blocking, software used for econometric analysis and 
type of qualitative method used. We observed that the mean 
and median sample size were 728 and 401, respectively, with 
most samples including patients. We also observed that half 
of the studies used blocking and most studies used Stata for 
econometric analysis. Interviewing was the most popular 
qualitative research method used alongside DCEs.
The observed increase in the total number of DCEs in 
health economics was similar to the trend reported in prior 
reviews [6, 7, 11], but less consistent from year to year 
(Fig. 3). This less consistent increase might be explained 
by the presence of many competing stated preference meth-
ods [4, 5, 347]. We hypothesise that other methods may be 
increasing in popularity or becoming more useful in health 
settings [348]. Examples of such methods may include BWS 
case 1 and case 2 [349–351], which were not included in 
this review. Additionally, in this review, we excluded a sig-
nificant number of studies (n = 31) making methodological 
considerations about DCEs rather than conducting empiri-
cal research. The presence of such studies may indicate that 
knowledge about DCEs in health has increased and there 
is more focus on studies to develop the method. Exam-
ples include simulation studies about experimental design, 
studies comparing the outcomes of a DCE to other stated 
preference method outcomes and studies examining differ-
ent model specifications [352–354]. This might be another 
explanation for the less consistent increase in DCE applica-
tion studies.
The common use of fractional designs, as described in 
prior reviews [6, 7], has continued. This review also found 
that main effects DCEs continue to dominate; however, there 
is a downwards trend as DCE designs incorporate two-way 
interactions more often. This is in line with the recommen-
dations of Louviere and Lancsar [12], who suggest inclusion 
of interaction terms should be explored in the experimental 
design stage. Ngene became the most popular software tool 
in the current review period for generating experimental 
designs, while D-efficient designs became the most popu-
lar method to create choice sets. Perhaps as a consequence 
of the rise in software-generated designs, this review also 
showed that an increasing percentage of articles did not 
include information about experimental design features 
such as the design plan. Omitting this type of information 
might inhibit quality assessment and reduce confidence in 
the results. Future research might focus on the specific rea-
sons why such information is missing and the impact of the 
missing information on quality assessment of DCEs. One 
potential reason for omitting methodological details is the 
journal word limit. When confronted with a low word limit, 
authors should consider using online space to report addi-
tional design and analysis details.
In addition to these observations about the generation of 
experimental designs, we identified design information that 
would be helpful to report in DCEs and future systematic 
reviews. For example, prior reviews did not include informa-
tion about blocking, and although at least half of the DCEs 
we reviewed used blocking, 30% of the studies we reviewed 
did not include information about blocking. Blocking could 
be an important technique in light of the growing literature 
about the cognitive burden of DCEs and the impact of this 
cognitive burden on respondent outcomes [345]. However, 
blocking also has the disadvantage of requiring a larger sam-
ple size [345]. The approach described by Sándor and Wedel 
[355] might be another alternative to increase the validity 
of DCE outcomes in case of relatively small sample sizes or 
the investigation of preference heterogeneity.
Prior reviews identified a shift to more flexible econo-
metric analysis models [6, 7], which is not necessarily posi-
tive. This trend has continued in this review. Most studies 
included multinomial logit or mixed logit models. Although 
we did not formally extract information about variance esti-
mation, we noted that among the DCEs using multinomial 
logit models to analyse choice data, few reported robust or 
Huber-White standard errors (most studies reported ‘regu-
lar’ standard errors). Since these standard errors allow for 
more flexible substitution patterns and flexible variances, it 
is common in economics and econometrics to report these 
standard errors instead of ‘regular’ standard errors [356]. 
Also, in the presence of repeated observations from the 
same individuals, conventional standard errors are biased 
downward [357]. Thus, future DCEs in health economics 
could benefit from more appropriate treatment of clustered 
data (i.e. use of robust standard errors) and more complete 
reporting of econometric output.
In terms of analytical methods, we also observed some 
patterns in the exploration of preference and scale het-
erogeneity. We noted that, among the 39% of studies that 
used a mixed logit model, many treated heterogeneity as a 
nuisance, i.e. they used the mixed model to accommodate 
repeated measures but did not report additional information 
about the ‘mixed’ aspect of the data (e.g. standard devia-
tion estimates). Since preference heterogeneity is regarded 
as an important aspect within choice modelling, taking full 
advantage of the modelling results might help us understand 
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preference heterogeneity better [358]. With regard to scale 
heterogeneity, work by Fiebig et al. [346] indicated that other 
models such as the generalised multinomial logit and het-
eroskedastic multinomial logit models could be considered 
when analysing DCE data, to identify differences in scale 
when comparing preferences between groups of respondents 
[359]. Data from this review identified a small number of 
DCEs using such methods; for a more detailed breakdown, 
we refer readers to another review focussing on scale hetero-
geneity specifically [30]. However, it is important to mention 
that the generalised multinomial logit model should be used 
with caution since the ability of this model to capture scale 
heterogeneity has been questioned in the literature [360].
Articles by Vass and Payne [19] and Mott [20] describe 
issues influencing the degree to which DCE findings are 
used in healthcare decision-making (e.g. health-state valu-
ation and health technology assessment). These articles, 
rising popularity of the method, and interest from regula-
tors and funders suggest that DCEs could play an important 
role in real-world decision-making [361, 362]. However, 
concerns have been expressed about the validity, reliability, 
robustness and generalisability of DCEs [11, 363]. A key 
stage in understanding the robustness of DCEs is under-
standing whether stated preferences reflect ‘true’ pref-
erences as revealed in the market [10]. In this study, we 
observed that the number of studies testing external validity 
remained small. Future research should focus on identifying 
and resolving the methodological and practical challenges 
involved in validity testing, and on guiding the incorporation 
of DCEs into actual decision-making in healthcare. Another 
practice that may improve the robustness of DCEs and facili-
tate their use in healthcare decision-making is the increased 
use of qualitative methods to complement quantitative DCE 
analysis [363]. Prior reviews and additional literature sug-
gest that qualitative research methods can strengthen DCEs 
and other quantitative methods by facilitating numerous 
investigations such as (1) identification of relevant attributes 
and levels, (2) verification that respondents understand the 
presented information, and (3) learning about respondents’ 
decision strategies [6, 7, 11, 364]. These investigations can 
help determine whether respondents are making choices 
in line with the underpinning utility theories, thereby sup-
porting the legitimacy of the underlying assumptions. This 
review showed an overall upwards trend in the number of 
DCEs using qualitative methods to select attributes and lev-
els. This move towards a more mixed-methods approach has 
been observed by others, for example, the study by Ikenwilo 
et al. [365].
4.1  Strengths and Limitations
The current study has several strengths. First, the detailed 
data extraction was completed by each author individually, 
with the total number of articles approximately divided 
equally among authors because of the relative short time-
frame and the need to balance author burden with study 
quality. Additionally, a subsample of studies (20%) was 
double-checked by one author (V.S.) for quality control, 
which enhanced reliability. Second, this study identified 
trends in empirical DCEs by comparing outcomes from 
all prior reviews. Additionally, this study included aspects 
of empirical DCEs not investigated before, although these 
aspects were recognised in the literature as becoming more 
important in DCE research (e.g. blocking in experimental 
design and the type of qualitative methods used in a DCE). 
Third, our observation of less rapid growth in the number of 
empirical DCEs (compared to the growth observed in previ-
ous reviews) matches the trend in the preference research to 
focus on the broad range of stated preference methods avail-
able (rather than DCEs exclusively) [4, 5, 347].
A potential weakness of this study was the use of multiple 
reviewers with potentially different interpretations of DCE 
reports, which might have affected the data extraction and, 
as a consequence, the results presented. To limit inconsist-
ency between reviewers, all co-authors discussed the data 
extraction frequently and results were cross-validated by a 
single author (V.S.). Similarly, this inconsistency in inter-
pretation may also have occurred between the different 
review periods. Procedural information from the two most 
recent reviews was used to ensure consistency, and we are 
therefore confident the general trends reported and the con-
clusion that more detailed methods reporting is called for 
holds. Another potential weakness is the use of only one 
database (PubMed). However, like the authors of the prior 
reviews [6, 7], we do not expect the review findings to be 
significantly different when performing searches on other 
databases. Also, since we were interested in identifying 
trends and therefore maximising comparability between the 
different reviews, we preferred to restrict our searches to this 
single database. As with many systematic reviews, data were 
extracted from published manuscripts and online appendi-
ces. The results are therefore reliant on what was reported in 
the final article and do not necessarily reflect all activities of 
the authors. Trends presented could therefore reflect factors 
such as publication bias, journal scope, editor preferences, 
and word limits, as well as preferences of journal editors 
rather than actual practice. Additionally, although we did 
update the data extraction tool based on changes in the field, 
future research might benefit from updating other aspects 
of the systematic review protocol such as search terms and 
inclusion and exclusion criteria (e.g. inclusion of best–best 
scaling). Finally, although we believe that DCEs are both 
useful and common enough to deserve focused attention in 
this review, DCEs represent one method among many for 
examining health preferences, and other methods may be 
preferable depending on the circumstances [4].
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5  Conclusion
This study provides an overview of the applications and 
methods used by DCEs in health. The use of empirical DCEs 
in health economics has continued to grow, as have the areas 
of application and the geographic scope. This study identi-
fied changes in the experimental design (e.g. more frequent 
use of D-efficient designs), analysis methods (e.g. mixed 
logit models most frequently used), validity enhancement 
(e.g. more diverse use of internal validity checks), quali-
tative methods (e.g. upwards trend of qualitative methods 
used for attribute and level selection) and outcome measures 
(e.g. coefficients most frequently used). However, a large 
number of studies not reporting methodological details were 
also identified. DCEs should include more complete infor-
mation, for example, information about design generation, 
blocking, model specification, random-parameter estimation 
and model results. Developing reporting guidelines specifi-
cally for DCEs might positively impact quality assessment, 
increase confidence in the results and improve the ability 
of decision-makers to act on the results. How and when to 
integrate health-related DCE outcomes into decision-making 
remains an important area for future research.
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